International childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November–1 December 2000

Ch, Pui; Sallan, Stephen E.; Mv, Relling; Masera, Giuseppe; We, Evans

doi:10.1038/sj.leu.2402111

Cited by 42 publications

(17 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, many environmental factors (e.g. exposure to ionizing radiation and electromagnetic fields, parental use of alcohol and tobacco) have been investigated as potential risk factors of acute lymphocytic leukemia [8].…”

Section: Discussionmentioning

confidence: 99%

Study of genetic polymorphism of xenobiotic enzymes in acute leukemia

Eyada¹,

Ghonemy

Ghoroury

et al. 2007

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The work studied possible association between genetic polymorphisms of CYP2D6, GSTM1, GSTT1and NQO1 and altered susceptibility to leukaemia, correlating these genetic polymorphisms with clinical prognostic data, response to therapy and relapse. The study included 32 leukaemia patients, 19 with acute myeloid leukemia (AML) and 13 with acute lymphoid leukaemia (ALL), and 11 normal individuals (control group). Basic investigations for the diagnosis of AML and ALL were performed, including blood picture, bone marrow aspirate, cytochemistry and immunophenotyping for detection of subtypes. Detection of CYP2D6, NQO1, GSTM1 and GSTT1 genetic polymorphisms used a polymerase chain reaction-restriction fragment length polymorphism. A follow-up was made for association between the outcome of patients and different patterns of genetic polymorphisms. Results demonstrate a significant increase in the frequency of CYP2D6 wild-type and GSTM1 null genotypes in the acute leukaemia group compared with the control. Studying the relationship between polymorphisms of these genes and the outcome of our cases revealed the wild genotype of CYP2D6 significantly influenced the outcome of acute leukaemia particularly in AML cases, while GSTM1 null genotype was associated with bad prognosis among the ALL group. The study also revealed that patients with combined mutant CYP2D6/present GSTM1/present GSTT1 achieved the best prognosis, suggesting synergistic impact of these genetic polymorphisms on the outcome of acute leukaemia cases. This case-control study suggests a contribution of CYP2D6 and GSTM1 null variants in the development of acute leukaemia. In addition, GSTM1 and GSTT1 genotypes were apparently related to response, side effects and prognosis of patients with AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of genetic polymorphism of xenobiotic enzymes in acute leukemia

Eyada¹,

Ghonemy

Ghoroury

et al. 2007

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…(1) Despite these advances, cooperative group trials continue to identify subgroups of B-ALL patients with a greater risk for relapse following chemotherapy. (2, 3) These findings have resulted in intensification of therapy for patients deemed at high or very high-risk of relapse and conversely, de-escalation of therapy for those with a lower risk for relapse. Older age (≥10 years) at diagnosis has long been associated with an increased risk of B-ALL relapse (4, 5) and recently the Children's Oncology Group (COG) has identified age ≥13 years at the time of diagnosis as a very high-risk feature.…”

Section: Introductionmentioning

confidence: 99%

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Burke

Gossai

Wagner

et al. 2013

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Risk adapted therapy has been the cornerstone of treatment for pediatric B-precursor acute lymphoblastic leukemia (B-ALL). Recently, age (>13 years at diagnosis) has been identified as a very high-risk feature for chemotherapy treated pediatric B-ALL patients. Whether age at time of transplant is associated with poor outcomes in adolescents and young adults (AYA) is unknown. We hypothesized AYA receiving allogeneic hematopoietic cell transplantation (allo-HCT) would have greater relapse and inferior survival. We reviewed the outcomes in 136 consecutive patients (ages 0 to 30 years) with B-ALL who received myeloablative allo-HCT at our institution. Fifty-eight percent (n=79) were children <13 years of age and 42% (n=57) were AYA 13 to 30 years of age. Overall survival at 5-years was significantly lower in the AYA group [HR 1.74, 95% CI: 1.04–2.95; p=0.03]. In addition, AYA patients had a greater risk of transplant related mortality (TRM) at 1-year [HR 2.23, 95% CI: 1.01–4.90, p=0.05] but no difference in relapse [RR 0.85, 95% CI 0.41–1.76; p=0.66]. Based on this analysis, AYA patients undergoing allo-HCT for B-ALL have significantly inferior survival and greater TRM compared to children <13 years but no difference in relapse suggesting allo-HCT may overcome relapse in AYA. Further improvements in peri-transplant care are needed to limit complications in AYA patients.

show abstract

“…[1][2][3][4] Measurements of any of these variables has prognostic value in childhood ALL, but none predict the course of the disease with absolute precision. [5][6][7] The rate of clearance of leukemic cells from peripheral blood and bone marrow is a reflection of the cumulative effects of leukemia and host factors and should be a valuable indicator of treatment outcome. Indeed, the presence of circulating lymphoblasts after 1 week of single-agent or multiagent remissioninduction therapy [8][9][10][11][12] and the detection of blast cells in the bone marrow by using morphologic criteria during remissioninduction therapy [13][14][15] predict a higher incidence of relapse.…”

Section: Introductionmentioning

confidence: 99%